Future of Myelofibrosis: Anticipated Data and Emerging Therapies

EP: 1.Myelofibrosis: Characteristics and Subtypes

EP: 2.NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis

EP: 3.Understanding Myelofibrosis: Disease Spectrum and Impact on Quality of Life

EP: 4.Prognosis and Treatment Strategies in Myelofibrosis: Risk Assessment and Therapeutic Goals

EP: 5.NCCN Guidelines 2023: Updates in Myelofibrosis Management

EP: 6.NCCN Guidelines: Categories and Recommendations in Myelofibrosis

EP: 7.Integrating Momelotinib: NCCN Guidelines and Drug Comparison

EP: 8.Monitoring Myelofibrosis Treatment Response: Guidelines and Considerations

Now Viewing

EP: 9.Future of Myelofibrosis: Anticipated Data and Emerging Therapies

This is a video synopsis/summary of a Guidelines involving Aaron Gerds, MD, MS.

Gerds anticipates significant data from ASH 2023 ,focusing on the transformative potential of combination therapies in myelofibrosis. The spotlight is on the TRANSFORM-1 (NCT04472598) and the MANIFEST-2 (NCT04603495) clinical trials, both exploring combination therapies. Despite achieving primary end points of spleen volume reduction, secondary end points related to symptom burden were not met, prompting nuanced interpretations. Gerds stresses the importance of long-term follow-up to assess the durability of combination therapies. Beyond ASH 2023, he highlights promising emerging treatments, including the MDM-2 inhibitor navtemadlin and the IMPACT study (NCT02164513) with imetelstat, aiming to prolong survival. Acknowledging the dynamic landscape of myelofibrosis treatment, Gerds advises practitioners to collaborate with specialized centers for optimal patient care and participation in clinical trials, which is crucial for advancing the field. This segment provides insights into the evolving therapeutic landscape for myelofibrosis and underscores the need for ongoing research and collaboration.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.